Bowel-regularity studies use specific strains at 10^9–10^10 CFU/day for 2–8 weeks; do not extrapolate across strains
Reviewed · Published
Bifidobacteria
Anaerobic colon bacteria whose clinical effects depend on strain and population.
Established functions
- Anaerobic colon bacteria whose clinical effects depend on strain and population.
Dietary sources
- fermented milk
- normal infant gut microbiota
Claims and evidence
Claims that Bifidobacteria alone prevents or treats disease, or invariably improves health without deficiency, are unsupported.
Japanese reference amounts
- Japanese adults (age and sex as specified): No Japanese DRI established
Amounts studied
- Bowel-regularity studies use specific strains at 10^9–10^10 CFU/day for 2–8 weeks; do not extrapolate across strains
Tolerable upper limits
- No UL; safety data are limited in high-risk patients
Forms and bioavailability
Supplement forms: freeze-dried live strains, multi-strain blends
- Some strains are oxygen- and heat-sensitive; packaging and refrigeration affect survival.
Safety and interactions
Adverse effects
- temporary gas and bloating; very rare infection
Medicine and nutrient interactions
- antibiotics may reduce survival when taken together
Contraindications and cautions
- Premature infants and severely immunocompromised patients require specialist oversight.
Practical selection
- Compare Bifidobacteria amount per serving, form, allergens, and batch testing; prefer a single-ingredient product suited to the intended use.
Sources and review
- Probiotics and prebiotics global guidelineWorld Gastroenterology Organisation
Daiki Minaki (editorial and evidence review) ·